VCU-1012, also known as 1-quinazolin-2-ylpiperazine or as 3-azaquipazine, is a psychedelic drug of the arylpiperazine family related to quipazine (1-(2-quinolinyl)piperazine). It is a serotonin 5-HT2A receptor agonist and produces psychedelic-like effects in rodents similarly to quipazine, but lacks quipazine's serotonin 5-HT3 receptor agonism and associated gastrointestinal adverse effects like nausea and vomiting. The drug represents a novel structural class of psychedelics distinct from existing scaffolds.
Interactions
Pharmacology
Pharmacodynamics VCU-1012 is an agonist of the serotonin 5-HT2A receptor. It shows about half the affinity of quipazine for the serotonin 5-HT2A receptor (Ki = 986 nM and 1,777 nM, respectively). The drug is a partial agonist of the serotonin 5-HT2A receptor, with about half the activational potency of quipazine (VCU-1012, EC50Tooltip half-maximal effective concentration = 1,550 nM; EmaxTooltip maximal efficacy = 46%; quipazine, EC50Tooltip half-maximal effective concentration = 240 nM; EmaxTooltip maximal efficacy = 56%). In addition to the serotonin 5-HT2A receptor, VCU-1012 shows high affinity for the serotonin 5-HT2B receptor (Ki = 24–31 nM) and for the 5-HT3 receptor (Ki = 8.3–14 nM). It also shows affinity for a variety of other receptors and for monoamine transporters, including the norepinephrine transporter (NET) and the serotonin transporter (SERT). Although VCU-1012 binds to the serotonin 5-HT3 receptor, unlike quipazine, it does not act as an agonist of this receptor. Relatedly, VCU-1012 did not produce the gastrointestinal effects of quipazine in rodents and would be expected to lack associated side effects like nausea and vomiting in humans. It is unknown whether VCU-1012 acts pharmacologically as a serotonin 5-HT3 receptor antagonist. It is also unclear whether it acts as an agonist or antagonist at the serotonin 5-HT2B receptor. The drug dose-dependently and robustly induces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. This is fully blocked by the serotonin 5-HT2A receptor antagonist volinanserin. VCU-1012 produces prolonged antidepressant-like effects in rodents. It also produces anxiolytic-like effects. The drug produces psychoplastogenic effects as well, which were mediated by serotonin 5-HT2A receptor activation.
Chemistry VCU-1012, along with quipazine, represents a novel structural class of psychedelics distinct from tryptamines, phenethylamines, and lysergamides.
Synthesis The chemical synthesis of VCU-1012 has been described.
Analogues Other novel psychedelic analogues of quipazine besides VCU-1012 have also been described. Notable psychedelic analogues of VCU-1012 besides quipazine include 2-naphthylpiperazine (2-NP) and VCU-1021 (3-methoxyquipazine).
History VCU-1012 was first described in the scientific literature by Jessica Maltman and Richard Glennon and colleagues at Virginia Commonwealth University (VCU) in 2024. It may have therapeutic potential and possible medical applications.
See also Arylpiperazine Quipazine List of miscellaneous serotonin 5-HT2A receptor agonists
References



